University Mulitiprofile Hospital for Active Treatment Sv.Georgi, Bulgaria Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2011
NCT01306461
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

tafluprost (zioptan) (1 trial)

timolol (blocadren) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Ocular Hypertension (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2